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aBStraCt 
Ameloblastic fibrosarcoma (AFS) is a rare malignant tumor characterized by benign epithelial component within a malignant fibrous 
stroma. It occurs as a de novo lesion or from a previous ameloblastic fibroma. The aim of this paper is to report an aggressive and 
recurrent case of AFS in the maxilla of a 38-year-old patient. Histopathological diagnosis can be challenging, especially when it is based 
on incisional biopsy specimens. Hence, this report highlights not only the importance of the histological features for diagnosis but also 
the clinical behavior of AFS based on current literature evidence.   
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introDuCtion
Ameloblastic fibrosarcoma (AFS) is an extremely rare 
malignant odontogenic neoplasm. To date, about 85 cases have 
been published in the English literature. AFS is defined by the World 
Health Organization (WHO) as a neoplasm structurally similar 
to ameloblastic fibroma (AF), but with its ectomesenchymal 
component showing sarcomatous appearance(1, 2). It can arise 
from a pre-existing AF or as a de novo lesion(3). In addition, it 
mainly affects males during the third decade of life. The mandible 
is the most common region and its main clinical features 
include swelling and pain(1). In this report, we describe a case of 
an aggressive AFS in the maxilla. New data on this uncommon 
neoplasm is also provided in order to guide future studies.
CaSE rEPort
A 38-year-old male patient was referred to the Head and Neck 
Surgery Service with a large firm swelling on the left side of maxilla. 
The patient mentioned that the swelling had shown fast growth 
over a period of one month. Pain and tenderness were not reported. 
Extra-oral examination showed facial asymmetry characterized by 
enlargement of the malar and lateral region of the nose. No palpable 
lymph nodes were present. Initial intra-oral examination showed an 
extensive lesion with tumoral aspect in the region of teeth 23 to 27. 
Preoperative hematological exams, radiographs, and computed 
tomography (CT) were requested, and an incisional biopsy 
suggested the diagnosis of “atypical ameloblastoma”. Two weeks after 
biopsy, the lesion had doubled in size. It showed an exophytic growth 
pattern and ulcerated appearance, with necrosis and formation of 
pseudomembrane (Figures 1 and 2). The patient had difficulties 
in eating, reduced mouth opening and altered phonation. Marked 
weight loss in the latest few days was also reported. Based on the 
clinical conditions, a medial maxillectomy with safety margins was 
performed. The histopathological analysis revealed benign epithelial 
islands similar to those of follicular ameloblastoma. The islands 
were composed of peripheral columnar or cuboidal cells arranged 
in a palisading pattern. Polyhedral cells resembling the stellate 
reticulum were found in the center of the islands. The epithelial 















figurE 2 − Intraoral view of the primary lesion showing an exophytic and ulcerated 
appearance
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stroma. This consisted of hypercellular connective tissue with plump 
polygonal to fusiform stromal cells, which showed mild to moderate 
cytological atypia. Mitotic cells were dispersed throughout the lesion. 
A final diagnosis of AFS was performed (Figures 3-5). Evaluation 
after 15 days of surgery showed no intercurrences. Four months 
after the treatment, the patient showed good extra-oral healing 
(Figure 6). However, a new lesion indicating recurrence was detected 
at the treated area (Figure 7). New surgical removal associated to 
adjuvant radiotherapy was planned. Unfortunately, the patient 
refused to undergo further interventions and died four months later.
figurE 1 − Extraoral asymmetry involving the left side of maxilla
figurE 3 − Mixed epithelial and mesenchymal components (HE, 200×)
HE: hematoxylin and eosin.
figurE 4 − High cellularity with mild cellular pleomorphism (HE, 200×)
HE: hematoxylin and eosin.
figurE 5 − Mild pleomorphism and presence of numerous malignant cells (HE, 400×)
HE: hematoxylin and eosin.
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figurE 6 − Extraoral view during follow-up
figurE 7 − Recurrence after treatment
DiSCuSSion
Malignant odontogenic tumors (MOTs) correspond to just a 
small percentage of the odontogenic neoplasms, with an incidence 
ranging from 0% to 6.1%. Among MOTs, odontogenic sarcomas 
are much less frequent than carcinomas(3). AFS is considered to be 
the malignant counterpart of AF, consisting of benign odontogenic 
epithelium with malignant mesenchyme(4).
In the present case, the tumor affected the posterior region of 
the maxilla of a 38-year-old male patient. According to a literature 
review, AFS is really more common in males(4-7). On the other hand, 
only 84 cases of AFS have been reported in the literature since its 
first description, with 63 involving the mandible and only 21 the 
maxilla, as search in the literature up to June 2016 demonstrated.
The history of the present case suggests that the tumor was 
probably a de novo lesion, since the patient had no history of 
previous surgery or diseases involving the mandibular region. 
Carlos-Bregni et al. (2003)(1) observed that approximately one-
third of all AFS derived from a previous AF. There is heterogeneity 
of signs and symptoms in AFS, with pain and swelling being the 
most common features(3). The male-to-female ratio is 1.6:1(1). 
The size of the tumor also varies and is related to the time spent for 
a final diagnosis. We observed that the tumor had grown rapidly 
from the initial clinical exam until the time of surgery. This fast 
growth resulted in serious functional consequences for the patient 
and weight loss.
The initial diagnosis suggestive of ameloblastoma in our 
case was made on the basis of an incisional biopsy. Establishment 
of a correct diagnosis of AFS may be challenging because well-
differentiated malignant areas may resemble other benign 
odontogenic tumors, such as ameloblastomas and AF(5). Thus, 
careful histopathological examination is critical. The degree of 
malignancy is determined based on some parameters, such as 
cellularity, palisade pattern, number of mitosis and atypia(5). In 
our case, some areas showed hypercellularity, pleomorphism and 
mild mitosis activity in the mesenchymal component, findings 
that are indicative of AFS. Unfortunately, there are no helpful 
immunohistochemical (IHC) markers that could improve final 
diagnosis. Therefore, the diagnosis of AFS using hematoxylin and 
eosin staining remains the gold pattern. An IHC panel composed 
of epithelium markers may be useful in identifying epithelial nests 
in cases whose epithelial component is rather bland, and thus, 
excluding the pure sarcomas. In our case, considerable epithelium 
nests were detected. Hence, IHC evaluation was not necessary to 
support the diagnosis, because the histopathological aspects 
described in our case are typical of AFS(1, 6).
Recurrence is common in AFS, with 37% of the reported cases 
having at least one episode(1). In contrast, metastasis is not a 
major characteristic(4). Fatal cases have usually been associated 
with uncontrolled local infiltration and numerous recurrences(5, 6). 
Among the 84 cases published until now (including the present), 
15 patients (20%) died as a direct result of the AFS, and all had 
recurrent tumor. Data related to fatal cases are shown in the Table.
Some studies have found predictors of survival rate in oral 
squamous cell carcinoma, such as vascular endothelial growth 
factor A (VEGF-A) genetic polymorphisms, micro ribonucleic 
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taBLE − Features of the fatal AFS cases in the current English literature
Author Year of publication Age (years) Sex Localization Recurrence Metastasis AF Follow-up (months)
Pindborg(8) 1960 17 M     Maxilla y n n 26
Cina et al.(9) 1962 32   F Mandible   y n y 30
Muroya and Shigematsu(10) 1962 43 M   Mandible   y n NA 33
Peychl and Sazana(11) 1971 17   F   Maxilla y n n 54
Mori et al.(12)
 
1972 3.5   F Mandible   y n n 60
1972 40   F Mandible   y n y 228
Hatzifotiadis and Economou(13)
 
1973 15 M     Maxilla y n n 24
1983 27 M   Mandible   y y y 120
Takeda et al.(14)
 
1984 19 M     Maxilla y n y 114
1984 18   F Mandible   y n n 12
Park et al.(15) 1995 17 M   Mandible   y n n 3
Tajima et al.(16) 1997 14 M     Maxilla y n n 6
Yamagushi et al.(17) 2004 31 M   Mandible   y n NA NA
Kousar et al.(18) 2009 20   F Mandible   y y y 15
Amorim et al.(this study) 2016 38 M     Maxilla y n n 8
    Mean 23.4 60% 40% 60% 40% 100% 13.3% 30.5% Mean 52
AFS: ameloblastic fibrosarcoma; AF: ameloblastic fibroma; M: male; F: female; NA: not available.
acid (RNA) 99a and others(7, 19). These new markers should also 
be studied in AFS in order verify if it is possible to detect the 
most aggressive cases. A case report by Williams et al. (2007)(4) 
showed alterations of the p53 and c-KIT genes restricted to the 
sarcomatous component. Diffuse nuclear reactivity for p53 and 
Ki-67 in the atypical mesenchymal cells and diffuse cytoplasmic 
reactivity for Bcl-2 protein, alpha-smooth muscle actin (α-SMA) 
and vimentin were detected in another case of AFS(5).
In ameloblastomas, a significant relation between stromal 
CD10 and Ki-67 expression in cases of recurrent cases compared 
to non-recurrent has been described(20). Masloub et al. (2011)(21) 
concluded that higher expression of CD10 and osteopontin might 
be a useful tool to identify areas with locally invasive behavior and 
high risk of recurrence in ameloblastomas. Thus, such markers 
should be considered in the study of AFS and should be also 
analyzed in AF, since this lesion is a possible precursor of AFS. 
In our case, the surgical specimen showed features for diagnosis 
of AFS, and in some areas, hypercellular connective tissue with 
plump polygonal to fusiform stromal cells, which showed mild 
to moderate cytological atypia, and some mitotic cells dispersed 
throughout the lesion were identified. So, for diagnosis and 
management of the case, it was not necessary to perform 
immunohistochemical study.
In the case reported by Bertoni et al. (2016)(22), a low-level Ki-
67 expression was observed in AFS. The authors also reported that 
c-KIT gene (CD117) expression is associated with sarcomatous 
components of AFS, but not those of AF. Loss of heterozygosis 
(LOH) in the short arms of chromosomes 3 and 9, at the 3p24.3, 
9p22-p21, and 9p22 loci, was also evident in AFS. The allelic loss 
fraction was reported to be 74.6 compared with that of AF, and 
these findings suggest that genetic changes allow malignant 
transformation of AF.
Pourdanesb et al. (2015)(23) reported that clinicopathologic 
diagnosis at the first presentation is very important to 
distinguish AF from AFS, what can have a tremendous impact 
on prognosis and management. These authors reported 
the case of a 34-year-old woman with a recurrent, rapidly 
growing, debilitating lesion. The lesion had been previously 
misdiagnosed as ameloblastoma. 
In conclusion, the report of new cases of AFS is crucial to 
add further information, in relation to treatment, diagnosis 
and management. Based on current knowledge, it is possible 
to suggest the use of p53, Ki-67, Bcl-2, α-SMA marker, VEGF-A, 
genetic polymorphisms and microRNA 99a in order to evaluate the 
clinical behavior of AFS.
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rESuMo 
O fibrossarcoma ameloblástico (FSA) é um tumor maligno raro caracterizado pela presença de componente epitelial benigno em um 
tecido conjuntivo fibroso maligno. Pode desenvolver-se a partir de um fibroma ameloblástico ou como uma lesão nova. O objetivo 
deste estudo é relatar um caso de um FSA agressivo e recorrente em maxila em um paciente de 38 anos. O diagnóstico histopatológico 
desse tumor pode ser difícil, principalmente a partir de biópsias incisionais. Este trabalho também discute fatores em relação aos 
aspectos histopatológicos para o seu diagnóstico, assim como seu comportamento clínico, com base em revisão atual da literatura.
Unitermos: neoplasias; maxila; diagnóstico diferencial.
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